Phase
Condition
Williams Syndrome
Dyskinesias
Depression
Treatment
N/AClinical Study ID
Ages 18-79 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion criteria:
diagnosis of idiopathic Restless Legs Syndrome, confirmed by a score of at least 11 onthe RLS Diagnostic Index
certain severity of symptoms (at least score of 15 on the International Restless LegsScore (IRLS)
Have had RLS symptoms for at least 15 nights in the last four weeks.
< 6 hours of sleep in nights with RLS symptoms
MADRS (depression rating scale) score of at least 12 (= borderline to depression) atbaseline
Exclusion
Exclusion criteria:
any other sleep disorder that might interfere with the RLS symptoms or sleep (e.g.sleep apnea disorder, narcolepsy)
Secondary RLS due to diagnosis of renal insufficiency, polyneuropathy, pregnancy (seebelow), iron deficiency anemia
Any significant psychiatric disorders (e.g. schizophrenia, bipolar disorder);depression which by judgement of the investigator is caused by RLS, is not anexclusion criterion.
Current or past suicidality
medication known to trigger/aggravate/ cause or interfere with RLS symptoms (e.g. mostantidepressants, lithium, neuroleptics, opioids, carbidopa, clonidine, antihistamines,anticonvulsants etc.).
daytime RLS symptoms which require treatment (daytime: 10 a.m. until 6 p.m.).
concomitant movement disorders (e.g. Parkinson's Disease, dyskinesia, dystonia).
medical conditions with symptoms which could affect assessments of efficacy (e.g.diabetes, rheumatoid arthritis, fibromyalgia syndrome, cancer etc.).
Subjects taking any medication known to induce drowsiness or to affect sleep.
Subjects who are pregnant, lactating or of childbearing potential. Women ofchildbearing potential must use adequate contraception
clinically significant or unstable medical conditions (e.g. severe heart disease,severe liver or kidney disease etc.).
pain syndromes, caused by other disorders than RLS
excessive caffeine intake
diastolic blood pressure >110mmHg or <50mmHg or systolic blood pressure >180mmHg or <90mmHg at baseline.
Withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) orthe oral contraceptive pill (OCP) and/or certain drugs which are known to interactwith ropinirole (e.g. ciprofloxacin, cimetidine, tobacco, omeprazole).
Study Design
Connect with a study center
GSK Investigational Site
Ellwangen, Baden-Wuerttemberg 73479
GermanySite Not Available
GSK Investigational Site
Freiburg, Baden-Wuerttemberg 79104
GermanySite Not Available
GSK Investigational Site
Ostfildern, Baden-Wuerttemberg 73760
GermanySite Not Available
GSK Investigational Site
Ulm, Baden-Wuerttemberg 89081
GermanySite Not Available
GSK Investigational Site
Muenchen, Bayern 80331
GermanySite Not Available
GSK Investigational Site
Nuernberg, Bayern 90403
GermanySite Not Available
GSK Investigational Site
Regensburg, Bayern 93053
GermanySite Not Available
GSK Investigational Site
Unterhaching, Bayern 82008
GermanySite Not Available
GSK Investigational Site
Wuerzburg, Bayern 97070
GermanySite Not Available
GSK Investigational Site
Bad Saarow, Brandenburg 15526
GermanySite Not Available
GSK Investigational Site
Bad Homburg, Hessen 61348
GermanySite Not Available
GSK Investigational Site
Butzbach, Hessen 35510
GermanySite Not Available
GSK Investigational Site
Herborn, Hessen 35745
GermanySite Not Available
GSK Investigational Site
Kassel, Hessen 34128
GermanySite Not Available
GSK Investigational Site
Anklam, Mecklenburg-Vorpommern 17389
GermanySite Not Available
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern 19053
GermanySite Not Available
GSK Investigational Site
Wismar, Mecklenburg-Vorpommern 23966
GermanySite Not Available
GSK Investigational Site
Achim, Niedersachsen 28832
GermanySite Not Available
GSK Investigational Site
Goettingen, Niedersachsen 37073
GermanySite Not Available
GSK Investigational Site
Hildesheim, Niedersachsen 31134
GermanySite Not Available
GSK Investigational Site
Wolfsburg, Niedersachsen 38440
GermanySite Not Available
GSK Investigational Site
Bielefeld, Nordrhein-Westfalen 33647
GermanySite Not Available
GSK Investigational Site
Bochum, Nordrhein-Westfalen 44809
GermanySite Not Available
GSK Investigational Site
Dueren, Nordrhein-Westfalen 52349
GermanySite Not Available
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen 40212
GermanySite Not Available
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen 45879
GermanySite Not Available
GSK Investigational Site
Guetersloh, Nordrhein-Westfalen 33330
GermanySite Not Available
GSK Investigational Site
Hattingen, Nordrhein-Westfalen 45525
GermanySite Not Available
GSK Investigational Site
Juelich, Nordrhein-Westfalen 52428
GermanySite Not Available
GSK Investigational Site
Limburgerhof, Rheinland-Pfalz 67117
GermanySite Not Available
GSK Investigational Site
Dresden, Sachsen 01307
GermanySite Not Available
GSK Investigational Site
Halle, Sachsen-Anhalt 06118
GermanySite Not Available
GSK Investigational Site
Koethen, Sachsen-Anhalt 06366
GermanySite Not Available
GSK Investigational Site
Oldenburg, Schleswig-Holstein 26122
GermanySite Not Available
GSK Investigational Site
Gera, Thueringen 07551
GermanySite Not Available
GSK Investigational Site
Jena, Thueringen 07743
GermanySite Not Available
GSK Investigational Site
Berlin, 13156
GermanySite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.